Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aluminum hydroxide
Drug ID BADD_D02611
Description Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Indications and Usage For relief of heartburn and acid indigestion.
Marketing Status approved; investigational
ATC Code A02AB02
DrugBank ID DB06723
KEGG ID D02416
MeSH ID D000536
PubChem ID 10176082
TTD Drug ID D0EQ6V
NDC Product Code 12784-148; 67417-245; 12784-147; 12784-350; 67417-238; 0536-0091; 12784-149; 12784-433; 12784-455; 67417-237; 51927-5167; 67417-219; 12784-137; 12784-199; 12784-438; 12784-429; 55603-671; 12784-146; 12784-427; 55603-211
UNII 5QB0T2IUN0
Synonyms Aluminum Hydroxide | Hydroxide, Aluminum | Hydrated Alumina | Alumina, Hydrated | Alugel | Algeldrate | Rocgel | Brasivil | Dialume | Nephrox | Pepsamer | Alhydrogel | Amphojel | Basalgel | Aldrox
Chemical Information
Molecular Formula AlH3O3
CAS Registry Number 21645-51-2
SMILES [OH-].[OH-].[OH-].[Al+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005--Not Available
Rash papular23.03.13.017--Not Available
Rash scarlatiniform23.03.13.006--Not Available
Renal failure20.01.03.005--Not Available
Rhinorrhoea22.12.03.021--
Skin warm23.03.03.014--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Swelling08.01.03.015--Not Available
Vomiting07.01.07.003--
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Induration08.01.03.020--Not Available
Feeling of body temperature change08.01.09.012--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Neurogenic shock24.06.02.023; 17.02.10.025--Not Available
Injected limb mobility decreased08.02.03.053; 12.07.03.053--Not Available
Vaccination failure12.02.11.007; 08.06.01.069--Not Available
Vaccination site erythema23.03.06.027; 12.07.06.001; 08.02.06.001--Not Available
Vaccination site pain12.07.06.002; 08.02.06.002--Not Available
Vaccination site swelling08.02.06.004; 12.07.06.004--Not Available
Vaccination site warmth12.07.06.005; 08.02.06.005--Not Available
Vaccination site bruising24.07.06.033; 23.03.11.046; 12.07.06.006; 08.02.06.006--Not Available
Vaccination site induration12.07.06.007; 08.02.06.007--Not Available
Vaccination site rash23.03.13.032; 12.07.06.011; 08.02.06.011--Not Available
The 2th Page    First    Pre   2    Total 2 Pages